Drug Approvals from 2025 – Triumphs in the midst of challenges
The following infographic outlines key drugs that have been newly approved by the US FDA in 2025.
2025 proved to be a challenging year for the FDA, with a government shutdown leading to a pause in functioning for the body. Ultimately in 2025 there were 46 new drug approvals, which is less than in previous years.
This infographic highlights some of the most notable FDA-approved drugs of 2025, showcasing their potential impact on healthcare and the lives of millions worldwide.
From revolutionary treatments for rare diseases to advancements in oncology and chronic conditions, these approvals reflect the culmination of years of research, collaboration, and scientific progress. Each drug featured in this infographic represents a significant step forward in addressing unmet medical needs, improving treatment outcomes, and enhancing the quality of life for patients.
The graphic provides a concise overview of these drugs, including their therapeutic indications, mechanisms of action, and the conditions they aim to treat. It also underscores the importance of regulatory milestones in fostering innovation and ensuring the safety and efficacy of new therapies.
Whether you are a healthcare professional, researcher, or simply interested in the latest developments in medicine, this visual guide offers valuable insights into the transformative power of science and the ongoing efforts to combat complex health challenges.
Explore the infographic to learn more about the future of medicine in 2025!
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...